BTG plc: Board Changes
London, UK, 28 September 2007 – BTG plc (LSE: BGC), the life sciences company, today announces the following Board changes.
Professor Colin Blakemore and Giles Kerr are joining the Board as non-executive directors, effective from 1 October 2007.
Fred Weiss, who has been a non-executive director since 2001 and is Chairman of the Audit Committee, will retire from the Board in November after publication of the Group’s interim results when Giles Kerr will succeed him as Chairman of the Audit Committee.
Sir Brian Fender, a non-executive director of BTG since 1992 and Chairman since July 2003, will retire from the Board during 2008. A search is under way for his successor.
Sir Brian Fender commented:
“I am delighted that Colin Blakemore and Giles Kerr are joining BTG’s Board. Colin’s scientific and medical background, and his extensive network of contacts, will be of great benefit to the organisation. Giles’s industry and financial experience make him an ideal addition to the Board and a suitably skilled audit committee chairman to replace Fred Weiss, whose wise counsel and positive contributions to the company have been invaluable.
“Having served more than four years as Chairman and seen the Company established in the life sciences, it is time to plan for my succession. I am confident that BTG will attract a high-calibre individual to take over as Chairman and lead the Group through its next phases of growth."
Colin Blakemore, FMedSci, Hon FIBiol, Hon FRCP, FRS has been a Professor in the Medical School at Oxford University since 1979. He was Chief Executive Officer of the Medical Research Council from 2003 to 2007, and from 1996-2003 he was Director of the MRC Centre for Cognitive Neuroscience at Oxford. He is a past President of the British Neuroscience Association, the Physiological Society, the Biosciences Federation and the British Association for the Advancement of Science. Professor Blakemore studied Medical Sciences at Cambridge and completed a PhD at the University of California in Berkeley.
Giles Kerr has been Director of Finance of Oxford University since 2005 and is a fellow of Keble College, Oxford. He is a non-executive director of Elan Corporation and Victrex plc. From 1990-2004 he held a number of positions with Amersham PLC within finance and corporate development, culminating in his role as Group Finance Director from 1997-2004. From 1981-1990 he was an auditor and National Partner with Arthur Anderson & Co. A chartered accountant, Mr Kerr holds a degree in Economics from the University of York.
There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Services Authority Listing Rules.
For further information contact:
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741
+44 (0)7990 530605 (mobile)
Christine Soden, Chief Financial Officer
+44 (0)20 7575 1591
+44 (0)20 7831 3113
BTG in-licenses, develops and commercialises pharmaceuticals and other medical technologies. With a substantial and growing revenue stream of royalties and milestone payments from out-licensed products, BTG continues to strengthen its pipeline of preclinical and clinical development programmes. Active in the fields of oncology, diseases of ageing, neuroscience, drug repositioning and medical devices, BTG works from its offices in London, Philadelphia and Osaka with a global partner network of healthcare companies and research organisations. For further information, visit: www.btgplc.com.